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Abstract
Alzheimer’s disease (AD) is characterized by progressive cognitive impairment associated with accumulation of amyloid b-
peptide, synaptic degeneration and the death of neurons in the hippocampus, and temporal, parietal and frontal lobes of
the cerebral cortex. Analysis of postmortem brain tissue from AD patients can provide information on molecular alterations
present at the end of the disease process, but cannot discriminate between changes that are specifically involved in AD
versus those that are simply a consequence of neuronal degeneration. Animal models of AD provide the opportunity to
elucidate the molecular changes that occur in brain cells as the disease process is initiated and progresses. To this end, we
used the 3xTgAD mouse model of AD to gain insight into the complex alterations in proteins that occur in the hippocampus
and cortex in AD. The 3xTgAD mice express mutant presenilin-1, amyloid precursor protein and tau, and exhibit AD-like
amyloid and tau pathology in the hippocampus and cortex, and associated cognitive impairment. Using the iTRAQ stable-
isotope-based quantitative proteomic technique, we performed an in-depth proteomic analysis of hippocampal and cortical
tissue from 16 month old 3xTgAD and non-transgenic control mice. We found that the most important groups of
significantly altered proteins included those involved in synaptic plasticity, neurite outgrowth and microtubule dynamics.
Our findings have elucidated some of the complex proteome changes that occur in a mouse model of AD, which could
potentially illuminate novel therapeutic avenues for the treatment of AD and other neurodegenerative disorders.
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Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder which affects mainly the elderly population and it is the
most common form of dementia and cognitive impairment [1].
Considerable progress has been made in recent years towards
understanding the pathogenesis and underlying mechanisms of
AD. AD is characterized by widespread neurodegeneration
throughout the association cortex, limbic system and hippocam-
pus. Alterations in the processing of amyloid precursor protein
(APP), resulting in the accumulation of amyloid b-peptide (Ab) and
the formation of oligomers, leads to synaptic damage and
neurodegeneration. Deposition of Ab also occurs in the neuropil
and around the blood vessels, and has been shown to result in the
formation of neurofibrillary tangles [2–4]. Accompanying the
neuronal damage, there is activation of macrophage/microglial
cells and astroglial cells that produce specific cytokines and
chemokines. In the initial stages of AD, the neurodegenerative
process may target the synaptic terminals [5,6] and then propagate
to axons and dendrites, leading to neuronal dysfunction and
eventually to neuronal death [7]. Neurofibrillary tangle formation
with accumulation of phosphorylated tau is also an important
pathologic process in AD and has been linked to the cognitive
alterations in these patients [8].
The neurodegenerative process in AD is thought to initiate in
the entorhinal cortex and then disseminates into the hippocampus
[9] and neocortical regions in the temporal, parietal and frontal
lobes [10]. The perforant pathway connects neurons in the
entorhinal cortex layer 2 with the hippocampal dentate gyrus and
is considered to play an important role in early memory formation
[11]. The most significant correlate to the severity of the cognitive
impairment in AD is the loss of synapses in the frontal cortex and
limbic system [12]. This pathogenic process involves changes in
synaptic plasticity that includes alterations in the formation of
synaptic contacts, changes in dendritic spine morphology and
abnormal synaptic contact [13]. However, other cellular mecha-
nisms necessary to maintain synaptic plasticity may also be
affected in AD [5,14]. While the molecular alterations that result
in synaptic dysfunction in AD are presently unclear, oxidative
stress, perturbed cellular energy metabolism and calcium homeo-
stasis have been implicated [15].
Considerable progress has been made in recent years towards
gaining a better understanding of the pathogenesis of AD, and in
developing novel therapeutic approaches. In this regard, the
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and the generation of transgenic mouse models of AD that express
the mutant human genes have been invaluable. Studies of mice
expressing APP, presenilin-1 (PS-1) and/or tau mutations have
demonstrated the potential of strategies that reduce Ab accumu-
lation, increase Ab clearance, and reduce oxidative damage [16].
However, there are likely to be many additional factors involved in
AD pathogenesis that, once fully elucidated and understood, may
also provide novel approaches for preventing and treating AD. In
this study, we used the well characterized mass-tag labeling
proteomic technique, iTRAQ, to elucidate some of the complex
proteome changes that occur in a mouse model of AD. Using
3xTgAD mice that express mutant PS-1, mutant APP and mutant
tau [17], we performed a detailed proteomic analysis of a large
number of quantitatively differentially expressed proteins in the
hippocampal and cortical tissues of 16-month old 3xTgAD mice
compared to age-matched non-transgenic controls. Proteins
significantly altered in the 3xTgAD mice compared to controls
included those involved in synaptic plasticity, neurite outgrowth
and microtubule dynamics.
Results
Measurement of relative protein levels between control
and AD mice
Peptides generated from trypsin digestion of control and AD
brain proteins were labeled at their free amine sites using the
isobaric mass tag labels (control 114, 115: AD 116, 117), mixed
together and analyzed by reverse phase liquid chromatography
coupled to tandem mass spectrometry. Upon collision-induced
dissociation, the parent peptides were broken up and the
associated isobaric mass tags were released. The dissociation of
the parent peptide yielded a characteristic mass fragmentation
pattern (Fig. 1A–C) that enabled identification of the parent
protein by comparing this fragmentation fingerprint to theoretical
digests of proteins. Additionally the associated isobaric mass tags
Figure 1. Sample iTRAQ analysis and iTRAQ ratios (3xTgAD:control) for cortex and hippocampus. A–C. Semi-quantitative isobaric mass-
tag identification from a single MS/MS peptide collision-induced dissociation event. A. A full scan MS/MS event for a single identified parent ion with
its multiple b and y series daughter ions shown. The isobaric mass tag labels added were 114 and 115 for control samples and 116 and 117 for
3xTgAD samples. The red box displayed upon the MS/MS spectra is successively expanded in panels B and C to identify the low mass range end of
the MS/MS scan event, exposing the mass range up to 120 m/z. In this example the 3xTgAD samples yielded the greater overall amount of isobaric
mass tag shown by the greater peak volumes for the 116- and 117-labeled samples compared to the 114- and 115-labelled samples. D and E. iTRAQ
ratios of 3xTgAD versus control for cortex and hippocampus. D. Mean 116/117:114/115 isobaric mass tag ratios for samples resolved by MS/MS from
the cortex of both control and 3xTgAD mice. Proteins identified from peptides that displayed a ratio greater than or equal to 1.2 or less that or equal
to 0.8 are considered to be statistically different according to standard protocols from unity and therefore distinctly regulated compared to control. E.
Correlated data gathered from mixed control and 3xTgAD hippocampal samples.
doi:10.1371/journal.pone.0002750.g001
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controls.
ID Cortex protein
Q5NC92_MOUSE (Q5NC92) Novel histone H2A family member 5.7
Q8R1M2_MOUSE (Q8R1M2) H2A histone family member J 4.5
Q6PDS7 (Q6PDS7) Histone 1h4h 3.75
H2A1_MOUSE (P22752) Histone H2A.1 3.59
PEP19_MOUSE (P63054) PEP-19 3.5
Q9D9Y2_MOUSE (Q9D9Y2) Adult male testis cDNA: tubulin alpha 7 3
VDAC1_MOUSE (Q60932) Voltage-dependent anion-selective anion channel 1 (VDAC1) 3
ATPD_MOUSE (Q9D3D9) ATP synthase delta 2.9
GSTP1_MOUSE (P19157) Glutathione S-transferase P1 2.88
BASP_MOUSE (Q91XV3) Brain acid soluble protein 1 (BASP1 protein) (Neuronal axonal membrane protein NAP-22) 2.88
Q71B07 (Q71B07) Transmembrane protein 2.67
SNP25_MOUSE (P60879) Synaptosomal-associated protein 25 (SNAP-25) (Synaptosomal-associated 25 kDa protein) 2.66
CYC2_MOUSE (P00015) Cytochrome c 2.6
AMPH_MOUSE (Q7TQF7) Amphiphysin 2.55
SYUA_MOUSE (O55042) Alpha-synuclein (Non-A beta component of AD amyloid) (Non-A4 component of amyloid precursor) (NACP) 2.5
Q6P5D0 (Q6P5D0) Dihydropyriminidase like-2 2.46
1433Z_MOUSE (P63101) 14-3-3 protein zeta/delta (Protein kinase C inhibitor protein 1) (KCIP-1) (SEZ-2) 2.45
ATP5E_MOUSE (P56382) ATP synthase epsilon 2.4
PKP3_MOUSE (Q9QY23) Plakophilin 2.33
Q8CEV2_MOUSE (Q8CEV2) 12 days embryo head cDNA: gyceraldehyde-3-phosphate dehydrogenase homolog 2.27
Q8VCE0 (Q8VCE0) Na+/K+ ATPase alpha 3 subunit 2.25
G3P_MOUSE (P16858) GAPDH 2.2
Q3TUZ9 (Q3TUZ9) Adult male tongue 2.2
TBA1_MOUSE (P68369) Alpha 1 tubulin 2.2
SYN1_MOUSE (O88935) Synapsin 2.15
ATP4A_MOUSE (Q64436) K+ transporting ATPase chain 1 2.14
STXB1_MOUSE (O08599) Syntaxin-binding protein 2.12
TBA4_MOUSE (P68368) Tubulin alpha4 chain 2.11
DYL2_MOUSE (Q9D0M5) Dynein 2.11
PPIA_MOUSE (P17742) Peptidylprolyl cistransisomerase A 2.08
Q9CXK3_MOUSE (Q9CXK3) 14,17 days embryo head cDNA: alpha actin 2.03
CYC_MOUSE (P62897) Cytochrome c somatic 2
SNAB_MOUSE (P28663) Beta soluble NSF 2
TBA2_MOUSE (P05213) Alpha tubulin 2
CLCB_MOUSE (Q6IRU5) Light chain clathrin 1.94
HBAZ_MOUSE (P06467) Hemoglobin zeta subunit 1.92
Q4VBD1_MOUSE (Q4VBD1) Hypothetical protein AK190093 1.8
Q6ZQ49_MOUSE (Q6ZQ49) MKIAA0778 1.8
MAP2_MOUSE (P20357) MAP-2 1.8
Q3U452 (Q3U452) NOD-derived CD11+ve dendritic cells 1.78
STMN2_MOUSE (P55821) Stathmin-2 1.78
KCRB_MOUSE (Q04447) Creatine kinase B 1.77
COF2_MOUSE (P45591) Coflin 1.77
TPM3_MOUSE (P21107) Tropomyosin alpha 3 chain 1.75
HXK1_MOUSE (P17710) Hexokinase 1.75
AT1A4_MOUSE (Q9WV27) Na+/K+ ATPase chain 4 1.75
SYPH_MOUSE (Q62277) Synaptophysin (Major synaptic vesicle protein p38) (BM89 antigen) 1.75
1433E_MOUSE (P62259) 14-3-3 epsilon 1.74
Q8BWN0_MOUSE (Q8BWN0) Adult pancreas islet cell cDNA: tyrosine 3-monooxygenase 1.7
Q922A0 (Q922A0) Eno2 1.7
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AT1A2_MOUSE (Q6PIE5) Na+/K+ transporting ATPase 1.7
ALDOA_MOUSE (P05064) Fructose bisphosphate aldolase A 1.66
ARL11_MOUSE (Q6P3A9) ARF-like 11 1.66
GNAO2_MOUSE (P18873) Go alpha 2 1.65
ENOA_MOUSE (P17182) Alpha enolase 1.64
Q5M9J7 (Q5M9J7) NADH dehydrogenase (Ubiquinone) Fe-S protein 6 1.62
STMN1_MOUSE (P54227) Stathmin 1.6
ARF6_MOUSE (P62331) ARF6 1.6
TPM2_MOUSE (P58774) Tropomyosin beta chain (Tropomyosin 2) 1.59
GBG2_MOUSE (P63213) Guanine nucleotide-binding protein G(I)/G(S)/G(O) gamma-2 subunit (G gamma-I) 1.58
LATS1_MOUSE (Q8BYR2) Serin/threonine-protein kinase LATS1 1.57
Q3U764 (Q3U764) Bone marrow macrophage cDNA: heat shock protein 8 1.56
PGK1_MOUSE (P09411) Phosphoglycerate kinase 1 (EC 2.7.2.3) 1.555
TBB3_MOUSE (Q9ERD7) Tubulin beta3 chain 1.55
Q8JZW6 (Q8JZW6) Rpgr protein 1.55
Q8C5K4 (Q8C5K4) Adult male olfactory brain cDNA: microtubule associated protein tau 1.55
GNA12_MOUSE (P27600) G protein Xla 1.55
O55129 (O55129) STOP protein 1.55
Q3TUI2 (Q3TUI2) Protein BAT4 1.5
Q99K52 (Q99K52) Calmodulin-like 3 1.5
COX6C_MOUSE (Q9CPQ1) Cytochrome c oxidase polypeptide Vic 1.5
SODC_MOUSE (P08228) Superoxide dismutase 1.48
Q91ZZ3 (Q91ZZ3) Beta synuclein 1.46
HBB1_MOUSE (P02088) Hemoglobin beta 1 subunit 1.45
FKB1A_MOUSE (P26883) Rotamase 1.45
P25A_MOUSE (Q7TQD2) Tubulin polymerization protein (TPPP) 1.44
Q9R0S6 (Q9R0S6) Beta-1-globin (Fragment) 1.44
ARF5_MOUSE (P84084) ADP-Ribosylation factor 5 1.43
Q9D2U9 (Q9D2U9) Adult male cerebellum cDNA: histone H2B 1.43
MBP_MOUSE (P04370) Myelin basic protein 1.42
HBA_MOUSE (P01942) Hemoglobin alpha subunit 1.42
Q3TBV8 (Q3TBV8) NOD-derived CD11+ve dendritic cell cDNA: pyruvate kinase 1.41
KCRU_MOUSE (P30275) Creatine kinase, ubiquitous mitochondrial precursor (EC 2.7.3.2) (U-MtCK) (Mia-CK) 1.41
Q8VC46 (Q8VC46) Cortex ubc protein 1.4
Q9DD04 (Q9DD04) Adult male kidney cDNA clone 061: ADP ribosylation factor 4 1.4
VATE_MOUSE (P50518) Vaculoar ATP synthase subunit E 1.4
HBB2_MOUSE (P02089) Hemoglobin beta 2 subunit 1.39
TBB6_MOUSE (Q922F4) Tubulin beta chain 1.38
Q9CWF2 (Q9CWF2) ES cells cDNA 1.38
Q7TMM9 (Q7TMM9) Tubulin beta 2 1.38
FUS_MOUSE (P56959) RNA-binding protein FUS (Pigpen protein) 1.38
Q3UH19 (Q3UH19) Adult male brain cDNA RIKEN: microtubule associated protein tau 1.36
CLCA_MOUSE (O08585) Clathrin 1.36
TPIS_MOUSE (P17751) Triosephosphate isomerase 1.36
STIP1_MOUSE (Q60864) Stress-induced-phosphoprotein 1 (STI1) (Hsc70/Hsp90-organizing protein) (Hop) (mSTI1) 1.355
AT12A_MOUSE (Q9Z1W8) K+ transporting ATPase 1.35
TAU_MOUSE (P10637) Microtubule-associated protein tau (Neurofibrillary tangle protein) (Paired helical filament-tau) 1.35
Q9QZ83 (Q9QZ83) Gamma actin-like protein 1.34
CPLX2_MOUSE (P84086) Complexin-2 (Synaphin-1) (921-L) 1.34
ATPA_MOUSE (Q03265) ATP synthase alpha chain, mitochondrial precursor (EC 3.6.3.14) 1.34
Table 1. cont.
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AN32A_MOUSE (O35381) Acidic leucine-rich nuclear phosphoprotein 1.33
ACTG_MOUSE (P63260) Cytoplasmic actin 1.33
ALBU_MOUSE (P07724) Serum albumin precursor 1.33
TBA6_MOUSE (P68373) Tubulin alpha-6 chain (Alpha-tubulin 6) (Alpha-tubulin isotype M-alpha-6) 1.32
Q9CY10 (Q9CY10) 13 days embryo liver cDNA, RIKEN full-length enriched library, clone:2510040B16 product:hemoglobin beta major chain 1.315
Q5XJF8 (Q5XJF8) Tubulin, alpha 1 1.305
TBBX_MOUSE (P68372) Beta tubulin 1.3
CXCC1_MOUSE (Q9CWW7) CpG binding protein 1.3
Q6W8Q3 (Q6W8Q3) Purkinje cell protein 4 like-1 1.29
CISY_MOUSE (Q9CZU6) Citrate synthase, mitochondrial precursor (EC 2.3.3.1) 1.29
UCRH_MOUSE (P99028) Ubiquinol-cytochrome c reductase complex 11 kDa protein, mitochondrial precursor (EC 1.10.2.2) 1.29
ATP5J_MOUSE (P97450) ATPsynthase coupling factor 6 1.25
UCRQ_MOUSE (Q9CQ69) Ubuiqinol 1 cytochrome c reductase complex 1.24
ROA3_MOUSE (Q8BG05) Heterogenous nuclear riboprotein A3 1.235
Q9R0S6 (Q9R0S6) Beta 1 globin 1.23
Q5D0E8 (Q5D0E8) Hbb-B1 protein 1.22
ABCG1_MOUSE (Q64343) ATP binding cassette subfamily G member 1.2
MT3_MOUSE (P28184) Metallothionein-3 (MT-3) (Metallothionein-III) (MT-III) (Growth inhibitory factor) (GIF) 21.2
Q3V2G3 (Q3V2G3) Adult male small intestine cDNA, RIKEN full-length enriched library, clone:2010010O17 product:Trypsinogen 16 homolog 21.22
STX1C_MOUSE (P61264) Syntaxin-1B2 (Syntaxin 1B) 21.24
PGAM1_MOUSE (Q9DBJ1) Phosphoglycerate mutase 1 (EC 5.4.2.1) (EC 5.4.2.4) (EC 3.1.3.13) (Phosphoglycerate mutase isozyme B) 21.25
ENOG_MOUSE (P17183) Gamma-enolase (EC 4.2.1.11) (2-phospho-D-glycerate hydro-lyase) (Neural enolase) 21.27
THIO_MOUSE (P10639) Thioredoxin (ATL-derived factor) (ADF) 21.27
Q3TVQ0 (Q3TVQ0) Osteoclast-like cell cDNA, RIKEN full-length enriched library, clone:I420044H02 product:formyltetrahydrofolate synthetase
domain containing 1
21.28
Q8BMV6 (Q8BMV6) 0 day neonate eyeball cDNA, RIKEN full-length enriched library, clone:E130116L18 product:hypothetical Type I antifreeze
protein
21.29
Q4VWZ5 (Q4VWZ5) Diazepam binding inhibitor, splice form 1b 21.3
HARP_MOUSE (Q8K3X6) Harmonin-interacting ankyrin-repeat containing protein (Harp) 21.3
ATPB_MOUSE (P56480) ATP synthase beta chain, mitochondrial precursor (EC 3.6.3.14) 21.31
ENSA_MOUSE (P60840) Alpha-endosulfine 21.34
Q505F3 (Q505F3) Minichromosome maintenance protein 10 21.35
VAMP2_MOUSE (P63044) Vesicle-associated membrane protein 2 (VAMP-2) (Synaptobrevin-2) 21.35
TOP2B_MOUSE (Q64511) DNA topoisomerase 2-beta (EC 5.99.1.3) (DNA topoisomerase II, beta isozyme) 21.35
CX7A2_MOUSE (P48771) Cytochrome c oxidase polypeptide VIIa-liver/heart, mitochondrial precursor (EC 1.9.3.1) 21.38
ATOX1_MOUSE (O08997) Copper transport protein ATOX1 (Metal transport protein ATX1) 21.38
Q9CRC1 (Q9CRC1) Adult male testis cDNA, RIKEN full-length enriched library, clone:4933425L11 product:fructose-bisphosphate aldolase A 21.4
Q80ZL4 (Q80ZL4) Mtap2 protein 21.4
Q4VWZ5 (Q4VWZ5) Diazepam binding inhibitor, splice form 1b 21.42
Q80X68 (Q80X68) Citrate synthase-like protein (Adult male testis cDNA, RIKEN full-length enriched library, clone:492 21.43
GPM6B_MOUSE (P35803) Neuronal membrane glycoprotein M6-b (M6b) 21.5
SPA4L_MOUSE (Q9DA32) Sperm-associated antigen 4-like protein 21.52
Q78PG9 (Q78PG9) Coiled-coil domain-containing protein 25 21.52
Q8C2C1 (Q8C2C1) 2 days neonate thymus thymic cells cDNA, RIKEN full-length enriched library, clone:E430030L01 product: hypothetical protein 21.6
PRVA_MOUSE (P32848) Parvalbumin alpha 21.7
UBIQ_MOUSE (P62991) Ubiquitin 21.8
VAMP3_MOUSE (P63024) Vesicle-associated membrane protein 3 (VAMP-3) (Synaptobrevin-3) (Cellubrevin) (CEB) 22.4
Q6PHZ2 (Q6PHZ2) Calcium/calmodulin-dependent kinase II 22.5
VKORL_MOUSE (Q6TEK5) Vitamin K epoxide reductase complex subunit 1-like protein 1 (VKORC1-like protein 1) 23.4
FBRL_MOUSE (P35550) Fibrillarin (Nucleolar protein 1) 23.4
doi:10.1371/journal.pone.0002750.t001
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ID Hippocampal protein
AMPH_MOUSE (Q7TQF7) Amphiphysin 3.22
MBP_MOUSE (P04370) Myelin basic protein (MBP) (Myelin A1 protein) 2.54
TCTP_MOUSE (P63028) Translationally-controlled tumor protein (TCTP) (p23) (21 kDa polypeptide) (p21) 2.52
HBE_MOUSE (P02104) Hemoglobin epsilon-Y2 subunit (Hemoglobin epsilon-Y2 chain) (Epsilon-Y2-globin) 2.4
HBB2_MOUSE (P02089) Hemoglobin beta-2 subunit (Hemoglobin beta-2 chain) (Beta-2-globin) (Hemoglobin beta-minor chain) 2.4
Q9R0S6 (Q9R0S6) Beta-1-globin (Fragment) 2.225
Q8R5L1 (Q8R5L1) P32-RACK (Complement component 1, q subcomponent binding protein) 2.18
MAP2_MOUSE (P20357) Microtubule-associated protein 2 (MAP 2) 2.16
Q91V86 (Q91V86) 11 days embryo whole body cDNA, RIKEN full-length enriched library, clone:2700082N11 product:hemoglobin beta 2.14
P25A_MOUSE (Q7TQD2) Tubulin polymerization-promoting protein (TPPP) 2.1
CPLX2_MOUSE (P84086) Complexin-2 (Synaphin-1) (921-L) 2.01
STX1C_MOUSE (P61264) Syntaxin-1B2 (Syntaxin 1B) 2
SYUA_MOUSE (O55042) Alpha-synuclein (Non-A beta component of AD amyloid) (Non-A4 component of amyloid precursor) (NACP) 1.95
Q9JI95 (Q9JI95) CPN10-like protein 1.88
CH10_MOUSE (Q64433) 10 kDa heat shock protein, mitochondrial (Hsp10) (10 kDa chaperonin) (CPN10) 1.87
Q921J3 (Q921J3) Dnajc5 protein 1.82
S100B_MOUSE (P50114) S-100 calcium-binding protein beta subunit (S-100 protein, beta chain) 1.8
PRVA_MOUSE (P32848) Parvalbumin alpha 1.78
Q8K0Z5 (Q8K0Z5) Tropomyosin 3, gamma 1.78
NUYM_MOUSE (Q9CXZ1) NADH-ubiquinone oxidoreductase 18 kDa subunit, mitochondrial precursor (EC 1.6.5.3) (EC 1.6.99.3) 1.77
FUS_MOUSE (P56959) RNA-binding protein FUS (Pigpen protein) 1.75
SYPH_MOUSE (Q62277) Synaptophysin (Major synaptic vesicle protein p38) (BM89 antigen) 1.75
GBG2_MOUSE (P63213) Guanine nucleotide-binding protein G(I)/G(S)/G(O) gamma-2 subunit (G gamma-I) 1.75
Q9D6X2 (Q9D6X2) Adult male tongue cDNA, RIKEN full-length enriched library, clone:2310046N07 product:peroxiredoxin 6 1.74
PEA15_MOUSE (Q62048) Astrocytic phosphoprotein PEA-15 1.73
ATP5H_MOUSE (Q9DCX2) ATP synthase D chain, mitochondrial (EC 3.6.3.14) 1.72
PEBP_MOUSE (P70296) Phosphatidylethanolamine-binding protein (PEBP) (HCNPpp) 1.706
HPCA_MOUSE (P84075) Neuron-specific calcium-binding protein hippocalcin 1.7
HINT1_MOUSE (P70349) Histidine triad nucleotide-binding protein 1 (Adenosine 59-monophosphoramidase) 1.7
Q8BGY2 (Q8BGY2) Eukaryotic translation factor 5A-2 1.68
NUPM_MOUSE (Q9DCJ5) NADH-ubiquinone oxidoreductase 19 kDa subunit (EC 1.6.5.3) (EC 1.6.99.3) (Complex I-19KD) (CI-19KD) 1.67
VATE_MOUSE (P50518) Vacuolar ATP synthase subunit E (EC 3.6.3.14) (V-ATPase E subunit) (Vacuolar proton pump E subunit) 1.64
O55107 (O55107) Basigin (Fragment) 1.633
PRDX5_MOUSE (P99029) Peroxiredoxin 5, mitochondrial precursor (EC 1.11.1.15) (Prx-V) (Peroxisomal antioxidant enzyme) 1.62
UBIQ_MOUSE (P62991) Ubiquitin 1.6
Q9CX22 (Q9CX22) 12 days embryo embryonic body between diaphragm region and neck cDNA, RIKEN full-length enriched library Cofilin 1 1.56
1433E_MOUSE (P62259) 14-3-3 protein epsilon (14-3-3E) 1.54
Q8BP43 (Q8BP43) 8 days embryo whole body cDNA, RIKEN full-length enriched library, clone:5730544G20 product:tropomyosin 1 alpha 1.53
VISL1_MOUSE (P62761) Visinin-like protein 1 (VILIP) (Neural visinin-like protein 1) (NVL-1) (NVP-1) 1.48
Q3V1V5 (Q3V1V5) Adult male brain cDNA, RIKEN full-length enriched library, clone:3526403B12 product:Spectrin alpha c 1.46
Q6PKE6 (Q6PKE6) Platelet-activating factor acetylhydrolase, isoform 1b, alpha2 subunit (Bone marrow macrophage cDNA) 1.45
Q8R4B4 (Q8R4B4) Down syndrome cell adhesion molecule-like protein (Fragment) 1.44
AATM_MOUSE (P05202) Aspartate aminotransferase, mitochondrial precursor (EC 2.6.1.1) (Transaminase A) 1.43
SH3G2_MOUSE (Q62420) SH3-containing GRB2-like protein 2 (EC 2.3.1.-) (SH3 domain protein 2A) (Endophilin 1) (SH3p4) 1.38
SODC_MOUSE (P08228) Superoxide dismutase [Cu-Zn] (EC 1.15.1.1) 1.371
NDKA_MOUSE (P15532) Nucleoside diphosphate kinase A (EC 2.7.4.6) (NDK A) (NDP kinase A) (Tumor metastatic process-associ 1.34
Q3UK59 (Q3UK59) CRL-1722 L5178Y-R cDNA, RIKEN full-length enriched library, clone:I730025H19 product:ATPase, H+ transporting VI
ATPase, H+ transporting, V1 subunit E
1.34
NUFM_MOUSE (Q9CPP6) NADH-ubiquinone oxidoreductase 13 kDa-B subunit (EC 1.6.5.3) (EC 1.6.99.3) (Complex I-13Kd-B) 1.315
TPIS_MOUSE (P17751) Triosephosphate isomerase (EC 5.3.1.1) (TIM) (Triose-phosphate isomerase) 1.29
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the mass labels for each parent peptide from the two sample types
(control and AD). Therefore, comparative peptide data between
control and AD samples could be obtained for multiple proteins
from one experiment. This process greatly reduces any variability
of peptide measurement for control versus AD samples.
The relative levels for a single exemplar protein (calmodulin-like
protein 3, Calml3, Q9D6P8/Q99K52) are shown in Fig. 1A–C, in
ID Hippocampal protein
UCHL1_MOUSE (Q9R0P9) Ubiquitin carboxyl-terminal hydrolase isozyme L1 (EC 3.4.19.12) (UCH-L1) 1.2
SNP25_MOUSE (P60879) Synaptosomal-associated protein 25 (SNAP-25) (Synaptosomal-associated 25 kDa protein) 1.2
PAK3_MOUSE (Q61036) Serine/threonine-protein kinase PAK 3 (EC 2.7.1.37) (p21-activated kinase 3) (PAK-3) (Beta-PAK) 21.25
CAP1_MOUSE (P40124) Adenylyl cyclase-associated protein 1 (CAP 1) 21.3
EFTU_MOUSE (Q8BFR5) Elongation factor Tu, mitochondrial precursor 21.35
ATPG_MOUSE (Q91VR2) ATP synthase gamma chain, mitochondrial precursor (EC 3.6.3.14) 21.35
ENOA_MOUSE (P17182) Alpha-enolase (EC 4.2.1.11) (2-phospho-D-glycerate hydro-lyase) (Non-neural enolase) (NNE) 21.36
AT1B1_MOUSE (P14094) Sodium/potassium-transporting ATPase beta-1 chain (Sodium/potassium-dependent ATPase beta-1 subunit) 21.4
Q80ZZ7 (Q80ZZ7) Ank2 protein (Fragment) 21.4
CH60_MOUSE (P63038) 60 kDa heat shock protein, mitochondrial precursor (Hsp60) (60 kDa chaperonin) (CPN60) 21.4
Q3U764 (Q3U764) Bone marrow macrophage cDNA, RIKEN full-length enriched library, clone:I830086I04 product:heat shock protein 8 21.4
SUCA_MOUSE (Q9WUM5) Succinyl-CoA ligase [GDP-forming] alpha-chain, mitochondrial precursor (EC 6.2.1.4) 21.4
TBB5_MOUSE (P99024) Tubulin beta-5 chain 21.43
DNM1L_MOUSE (Q8K1M6) Dynamin-1-like protein (EC 3.6.5.5) (Dynamin-related protein 1) (Dynamin family member proline-rich) 21.5
PAK1_MOUSE (O88643) Serine/threonine-protein kinase PAK 1 (EC 2.7.1.37) (p21-activated kinase 1) (PAK-1) (P65-PAK) 21.5
Q58ES7 (Q58ES7) Spna2 protein (Fragment) 21.51
CALX_MOUSE (P35564) Calnexin precursor 21.52
CRYM_MOUSE (O54983) Mu-crystallin homolog 21.53
Q6PCN2 (Q6PCN2) Ankyrin 2, brain 21.54
ATPB_MOUSE (P56480) ATP synthase beta chain, mitochondrial precursor (EC 3.6.3.14) 21.57
VATA1_MOUSE (P50516) Vacuolar ATP synthase catalytic subunit A, ubiquitous isoform (EC 3.6.3.14) (V-ATPase A subunit 1) 21.7
GRP78_MOUSE (P20029) 78 kDa glucose-regulated protein precursor (GRP 78) (Immunoglobulin heavy chain binding protein) 21.7
Q4VWZ5 (Q4VWZ5) Diazepam binding inhibitor, splice form 1b 21.74
DEST_MOUSE (Q9R0P5) Destrin (Actin-depolymerizing factor) (ADF) (Sid 23) 21.75
HS90B_MOUSE (P11499) Heat shock protein HSP 90-beta (HSP 84) (Tumor-specific transplantation 84 kDa antigen) (TSTA) 21.75
CLH_MOUSE (Q68FD5) Clathrin heavy chain 21.8
TBA6_MOUSE (P68373) Tubulin alpha-6 chain (Alpha-tubulin 6) (Alpha-tubulin isotype M-alpha-6) 21.8
TBA8_MOUSE (Q9JJZ2) Tubulin alpha-8 chain (Alpha-tubulin 8) 21.8
ERMP1_MOUSE (Q3UVK0) Endoplasmic reticulum metallopeptidase 1 21.88
GNAO2_MOUSE (P18873) Guanine nucleotide-binding protein G(o), alpha subunit 2 21.88
Q5XJF8 (Q5XJF8) Tubulin, alpha 1 22
Q9CRC1 (Q9CRC1) Adult male testis cDNA, RIKEN full-length enriched library, clone:4933425L11 product:fructose-bisphosphate aldolase A 22.12
PGK2_MOUSE (P09041) Phosphoglycerate kinase, testis specific (EC 2.7.2.3) 22.23
MK01_MOUSE (P63085) Mitogen-activated protein kinase 1 (EC 2.7.1.37) (Extracellular signal-regulated kinase 2) (ERK-2) 22.27
SPTA2_MOUSE (P16546) Spectrin alpha chain, brain (Spectrin, non-erythroid alpha chain) (Alpha-II spectrin) 22.4
Q3TBV8 (Q3TBV8) NOD-derived CD11c +ve dendritic cells cDNA, RIKEN full-length enriched library: pyruvate kinase 22.4
HS90A_MOUSE (P07901) Heat shock protein HSP 90-alpha (HSP 86) (Tumor-specific transplantation 86 kDa antigen) (TSTA) 22.67
EF1G_MOUSE (Q9D8N0) Elongation factor 1-gamma (EF-1-gamma) (eEF-1B gamma) 22.7
ACON_MOUSE (Q99KI0) Aconitate hydratase, mitochondrial precursor (EC 4.2.1.3) (Citrate hydro-lyase) (Aconitase) 22.73
DHPR_MOUSE (Q8BVI4) Dihydropteridine reductase (EC 1.5.1.34) (HDHPR) (Quinoid dihydropteridine reductase) 22.98
DPYL2_MOUSE (O08553) Dihydropyrimidinase-related protein 2 (DRP-2) (ULIP 2 protein) 23.5
Q5SQX7 (Q5SQX7) Cytoplasmic FMR1 interacting protein 2 (Fragment) 24.5
GDIC_MOUSE (Q61598) Rab GDP dissociation inhibitor beta-2 (Rab GDI beta-2) (GDI-3) 24.76
Q8VCE0 (Q8VCE0) Na+/K+-ATPase alpha 3 subunit 25.5
doi:10.1371/journal.pone.0002750.t002
Table 2. cont.
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than the levels of the same peptide from control animals (114, 115).
Global alterations in protein expression level in the
cortex and hippocampus of male control and AD animals
iTRAQ mass tag ratios were calculated for proteins with
reliable identifications (see Materials and Methods) based upon
their collision-induced dissociation fragmentation patterns. Ratios
of the AD mass tags (116, 117) compared to the control tags (114,
115) that were greater than 1.2 or less than 0.8, were considered to
be statistically different from unity, i.e. changed expression level of
the protein. The numbers of up-regulated and down-regulated
proteins are displayed in Figs. 1D and E. We found that generally
more proteins were detected in the cortical samples than in the
hippocampal samples. The specific proteins and their expression
alterations (fold change compared to control mass tag levels) are
listed for the cortex and hippocampus in Tables 1 and 2,
respectively.
Co- and contra-regulated protein expression levels in the
hippocampus and cortex
The numerous proteins identified from the hippocampus and
cortex and their expression level relative to control animals, were
arranged according to their expression and relative expression
levels in a four-way Venn diagram (Fig. 2: http://www.pangloss.
com/seidel/Protocols/venn.cgi). We found that there was a good
specificity between proteins regulated (either up or down) in the
cortex and in the hippocampus, i.e. no proteins were both up-
regulated and down-regulated in both the tissues. Additionally,
there was a greater similarity between the cortex and hippocampus
with respect to protein up-regulation as there were 16 proteins up-
regulated in both the cortex and hippocampus. In contrast, there
were only three proteins that were co-downregulated in both the
cortex and hippocampus. Similarly, when the diverse regulation of
protein expression was investigated, there were more proteins
(seven) that were up-regulated in the cortex and down-regulated in
the hippocampus, compared to three proteins down-regulated in
the cortex and up-regulated in the hippocampus. The multiple
expression and tissue combinations from the four-way Venn
diagram and the protein IDs are listed in Fig. 3. In Fig. 4 the
proteins co-regulated between the cortex and hippocampus in AD
animals compared to the controls are shown. It is interesting to
note that many of the co-upregulated proteins are involved in
synaptic neurotransmission (SNAP-25, complexin, synaptophysin,
alpha-synuclein), energy management (triosephosphate isomerase,
superoxide dismutase) and cytoskeletal dynamics (tubulin poly-
merization protein). The co-downregulated proteins were fewer in
number, but also seemed to be more selectively involved with
energy balance (e.g. ATP synthase, fructose bisphosphate aldolase
A). This could suggest that in the 3xTgAD animals there was an
increased attempt to maintain neuronal energy balance and
increase neurotransmitter secretion. In addition to these energy
metabolism proteins, there was also a concerted reduction of the
diazepam binding inhibitor protein (DBI).
Among the contra-regulated proteins between the hippocampus
and cortex (Fig. 5), some of the predominant phenotypes included
structural/stress proteins (tubulin, heat-shock protein 8) as well as
energy-related factors such as pyruvate kinase and the Na
+/K
+
ATPase alpha 3 subunit, which was selectively up-regulated in the
Figure 2. Four-way Venn diagram analysis for significantly regulated proteins in 3xTgAD compared to control from cortex and
hippocampus. A. Numbers of proteins existing in the 15 loci in the Venn diagram between the four paradigms, i.e. up- or down-regulation in cortex
or hippocampus. B. Key for loci in the four-way Venn diagram in A.
doi:10.1371/journal.pone.0002750.g002
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regulation of the heterotrimeric Gao G protein is interesting as this
G protein links many receptor signaling systems to ion channels
involved in maintaining neuronal excitability, e.g. the inward
rectifying potassium channels. With respect to the converse
scenario (down-regulated in cortex and up-regulated in hippo-
campus) the proteins in this specific subset are involved in
maintaining neuronal survival (parvalbumin), neurotransmission
(syntaxin) and protein processing (ubiquitin).
To verify the expression of a broad selection of proteins co- or
contra-regulated by AD in the hippocampus or cortex, western
blots were performed from tissue lysate samples resolved onto
PVDF membranes (Fig. 6). We verified the proteomic data that we
obtained using the iTRAQ technique by performing western blot
analyses for a total of 16 proteins that were significantly altered in
either the hippocampal or cortical tissues (compared to control)
and a protein (protein kinase C) that did not show significant
differences between wild-type and 3xTgAD tissues. The western
blot validation of these multiple proteins reinforced the power of
multi-protein analyses of complex samples such as hippocampal
and cortical tissue from AD animal models (Figure 6). To
demonstrate the relationships between the iTRAQ expression
ratios gained and the expression ratios observed for the same
proteins with western blots, the following mathematical procedure
was performed. The iTRAQ expression ratio for each protein, in
cortex or hippocampus, was divided by the mean ratio (of the two
3xTgAD samples compared to the two control samples) of western
blot expression ratio. Each of the protein values obtained were all
similar to unity (0.08.iTRAQ ratio/western ratio,1.2; Figure 6)
indicating a consistency of expression profile between iTRAQ and
western blot data.
Phenotypic functional group analysis of complex protein
alterations in AD brain compared to control brain
To utilize the wide range of data obtained on protein
alterations, we used a gene set analysis toolkit, WebGestalt ([18]:
http://bioinfo.vanderbilt.edu/webgestalt/) in which protein iden-
tifications were input using a Swiss-Prot ID for the proteins
identified. This toolkit allows the functional annotation of gene/
protein sets into gene-ontology (GO) functional groups and also
Figure 3. Murine protein accession ID numbers from four-way Venn diagram analysis and loci identification. The fifteen possible loci
from a four-way Venn diagram are listed in the alphabetical key from Figure 2. Loci that contain occupied (accession numbers) protein sets are
indicated in red and also in the descriptor lines for the loci.
doi:10.1371/journal.pone.0002750.g003
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Kyoto Encyclopedia of Genes and Genomes, http://www.
genome.jp/kegg/). Not only is functional annotation possible,
but an enrichment score can also be obtained of the frequency of
occurrence of a specific protein (or gene) within any given
experimental subset with respect to a species-specific background
set. Thus, an enrichment factor (observed frequency in input set/
expected expression frequency in background species set) can be
created that has a statistically testable value, indicating that the
protein (or gene) is specifically over- or under-represented in the
input sample group. When allotting proteins into functional
groups (GO) or physiological signaling pathways (KEGG), at least
two proteins were required to be independently placed into that
functional group before using any statistical analysis. The
significance of the representation of functional groups or pathways
in the AD samples versus control was assessed using a built-in
hypergeometric test with a p,0.05 cut-off. Input protein lists of
up- or down-regulated proteins were analyzed using the
Webgestalt software. The up-regulated and down-regulated
proteins from cortex or hippocampus once submitted to the
pathway algorithms, created the significantly (p,0.05) represented
functional groups shown in Fig. 7. To analyze correlations
between the functional groups significantly up- or down-regulated
in 3xTgAD mice versus controls, a four-way Venn diagram was
constructed. In this Venn diagram (Fig. 8.), the majority of
functional groups were singly represented in each of the tissue or
regulation direction paradigms. There were three significantly up-
regulated groups shared between the cortex and hippocampus
(ATP-synthesis-coupled proton transport, neurotransmitter secre-
tion, synaptic transmission; Fig. 9). In contrast, there were two
significantly over-represented pathways down-regulated in both
cortex and hippocampus (glycolysis, neurite morphology; Fig. 9).
There was one contra-regulated functional group (potassium
transport) which was up-regulated in the cortex while down-
regulated in the hippocampus, and there were two contra-
regulated functional groups (cell-cell signaling, regulation of
neurotransmitter levels) which were down-regulated in the cortex
but up-regulated in the hippocampus.
Phenotypic physiological signaling pathway analysis of
complex protein alterations in 3xTgAD versus control
mice
In a similar manner to the functional group classifications using
GO terms, the up- and down-regulated protein sets from the
cortex and hippocampus were also analyzed using the KEGG
pathway algorithm. From the analysis of the individual proteins, to
the functional GO group analysis, to this KEGG pathway analysis,
there is an ascending complexity of functional grouping. However,
with this widening of functionality there is also a greater capacity
for cross-over and inclusion of seemingly contradictory protein
expression effects as complex signaling pathways can encompass
diverse regulatory proteins. The significantly overrepresented
KEGG pathways in all four tissue and protein expression
regulation paradigms are shown in Fig. 10. Similarly to the GO
term analysis, we created a four-way Venn diagram to cross-
analyze relationships between the two central nervous tissues
studied (Fig. 11). As expected, there was a complicated relationship
between the different tissues and the up- or down-regulation of the
protein groups. Considering the nature of the sample and the
Figure 4. Co-regulated proteins between cortex and hippocampus in 3xTgAD mice compared to control. A. Proteins that were elevated
in their expression in 3xTgAD mice compared to control in both the cortex (blue) and hippocampus (red). B. Co-regulated proteins in 3xTgAD
animals that were diminished compared to control animals.
doi:10.1371/journal.pone.0002750.g004
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the two significantly co-upregulated (cortex and hippocampus)
signaling pathways include the Alzheimer’s disease pathway and
the neurodegenerative disorders pathway (Fig. 12). The presence
of these two pathways confirms the validity of mass protein
analytical techniques combined with unbiased multiprotein
annotation in predicting functional groups from complex tissue
samples. Interestingly with respect to maintenance of neuronal
energy balance, the only co-regulated pathway from the down-
regulated protein groups in cortex and hippocampus was the
insulin signaling pathway. A large cluster of functional signaling
pathways were up-regulated in the cortex and down-regulated in
the hippocampal samples, i.e. focal adhesions, gap junctions, long-
term depression (LTD), mitogen-activated/microtubule-asso-
cioated protein kinase (MAPK) signaling and regulation of actin
cytoskeleton. In contrast, only one signaling pathway was
represented significantly in the set of cortex down-regulated and
hippocampus up-regulated proteins, i.e. SNARE interactions.
Discussion
Neurological disorders such as AD are inherently complex in
that they involve the disruption of perhaps the most intricate entity
in existence, the neuronal network in the human brain. The
changes that occur in AD at the cellular and molecular levels
undoubtedly include both pathophysiological degenerative pro-
cesses and adaptive responses to counteract the disease process. In
this study we used an iTRAQ proteomic approach to elucidate
molecular alterations that may occur during the clinical course of
AD. We analyzed multiple protein expression patterns in the
cortex and hippocampus of 16 month-old 3xTgAD mice
compared to their age-matched controls. At this age, the 3xTgAD
mice exhibit considerable amyloid and tau pathology in the
hippocampal and cortical regions and they have learning and
memory impairments [17].
Quantitative protein expression data was obtained from four
groups of two pooled individuals for the cortex and the
hippocampus. As there is considerable discussion about the
relative merits of pooling tissues before analysis or pooling data
post individual analysis, we therefore decided to take a hybrid
approach. Our approach consisted of partial pooling of tissues.
Two animals were pooled (control (114) or 3xTgAD (116)) for a
single isobaric label but then another, completely separate, two-
animal pool was used for a second control (115) or 3xTgAD (117)
isobaric label set. While pooling of animal tissue does not
specifically reduce any inter-individual variation, it can however
dilute the differential expression effects between individuals. It is
clearly preferable to perform parallel investigations upon individ-
uals in a population sample and then to pool the individual data
sets, as this preserves any idiosyncrasies between animals or
subjects that can then be correlated later with specific expression
profiles. The only drawback for this analysis though is one of cost
to the investigator. Typically, tissue pooling is preferred when
either small amounts of tissue are available from individuals or
Figure 5. Contra-regulated proteins between cortex and hippocampus in 3xTgAD mice compared to control. A. Proteins that were
potentiated in 3xTgAD compared to control in the cortex and attenuated in the hippocampus of 3xTgAD compared to control. B. Proteins that were
potentiated in 3xTgAD compared to control in the hippocampus and attenuated in the cortex of 3xTgAD compared to control.
doi:10.1371/journal.pone.0002750.g005
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primary arguments supporting the practice of pooling biological
samples for large scale protein or gene analysis is the notion that
biological variation can be reduced by this practice [19]. However,
pooling can attenuate the effects of biological variation but not of
course the intrinsic cause of the biological variation itself [20]. The
basic assumption underlying sample pooling is that of biological
averaging, i.e. the measure of interest taken on the pool of samples
is equal to the average of the same measure taken on each of the
individual samples which contributed to the pool [21]. It has been
argued that even when biological averaging does not hold, pooling
can be of use and inferences concerning differential gene or
protein expression may not be adversely affected by tissue pooling
[20]. The significant alterations in proteins that were detected
using our hybrid method demonstrates that with this mixture of
biological averaging and parallel analysis, differential expression
can be assessed from small animal numbers. Employment of
unbiased parametric analysis of complex protein sets, as we have
used in this study, may greatly enhance the utility of mass
spectrometry as a tool to understand physiological changes
occurring in disease. Unbiased clustering of proteins into
functional groups (gene ontology) and especially pathways
(KEGG) allows a physiological ‘phenotype’ of the protein set to
be created that is not entirely dependent on specific protein
identities in the set. Hence with pathway analysis, variations in
output protein identifications (even in biological replicates) will be
compensated for by perhaps other proteins in the sample that also
can fall into and significantly populate a specific pathway group.
The nature of the output pathway phenotype, indicative of the
biology of the input sample, therefore may be more reproducible
(even between multiple mass spectrometry runs) as the parametric
analysis uses multiple protein identities to create a significantly
regulated group rather than using a single identity.
For the cortex, a total of 142 significantly regulated proteins
were identified (116 up-regulated, 26 down-regulated). For the
hippocampus a total of 91 significantly regulated proteins were
identified (49 up-regulated, 42 down-regulated). In many cases, the
proteins, and their direction of regulation were specific to either
Figure 6. Western blot analysis of a selected array of proteins significantly regulated in the cortex or hippocampus of 3xTgAD mice
compared to control. A. Representative western blots of loaded cortex protein resolved by SDS-PAGE and specifically western blotted with the
antisera indicated. Lanes 1 and 2 contain protein from the control cortices and lanes 3 and 4 from the cortices of 3xTgAD animals. B. Western blots
from protein extracted from hippocampal samples. The column format of the panel follows an identical format to panel A. C. Histogram depicting
the similarity between measured cortex protein iTRAQ expression ratios and the western blot expression ratios of 3xTgAD to wild-type. Mathematical
division of cortex iTRAQ expression ratios for multiple proteins by the western blot expression ratios yields values all near unity indicating a strong
agreement in expression data. D. Histogram demonstrates a similar (to panel C) close relationship between iTRAQ and western blot expression ratios
for proteins from the hippocampus. As each value for multiple proteins is near unity there is a strong agreement between iTRAQ expression and
western blot expression analysis for hippocampal proteins as well as cortical proteins.
doi:10.1371/journal.pone.0002750.g006
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subsets of co-regulated proteins and contra-regulated proteins, and
these protein sets are expected to hold more significance as they
represent specific commonalities and distinctions in how different
brain regions respond to a genetically-imposed pathological state.
The higher levels of superoxide dismutase (SOD) in the cortex
and hippocampus of the 3xTgAD mice compared to controls, is
consistent with previous data suggesting that oxidative stress is
increased in association with amyloid and neurofibrillary pathol-
ogies in AD patients and in mouse models of AD [15,19,20].
Additionally, the increased amount of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) in the cortex of 3xTgAD mice
compared to controls, could reflect the activation of neurodegen-
erative pathways, as recent findings have suggested that GAPDH
can promote neuronal death [21].
We identified distinct sub-groups of proteins with common
functional actions that were co-upregulated in both the hippo-
campus and cortex, in part due to or perhaps in response to, the
presence of the AD pathology. For example, we identified proteins
that are involved in synaptic transmission and vesicle exocytosis
such as SNAP-25, complexin-2, synaptophysin, amphiphysin and
alpha synuclein. It is interesting and perhaps revealing that these
up-regulations may seem paradoxical in light of many reports of
down-regulation of synaptic proteins in AD; however many of
these reports are from post-mortem tissue collected from human
patients with severe end-stage dementia [22]. One explanation for
the increase in synaptic proteins in 3xTgAD mice is that neurons
respond to the neuropathology in an attempt to ameliorate
synaptic transmission deficits. Similar modest increases in
synaptophysin and SNAP-25 have also been observed in other
animal models of AD [23]. The increased levels of alpha-synuclein
in the brain samples from 3xTgAD mice are consistent with the
reported accumulation of alpha-synuclein in the brains of AD
patients [24]. Interestingly, our finding of a paradoxical increase in
amphiphysin levels also seems consistent with AD pathology, as
Kelly and Ferreira [25] recently demonstrated increases in
hippocampal neuronal amphiphysin in response to an Ab load.
In addition to the group of proteins related to synaptic function,
our iTRAQ analysis identified another important cluster of
proteins involved in cytoskeletal dynamics, including MAP-2 and
tubulin polymerization promoting protein (TPPP). MAP-2 may
accumulate in the neurons of 3xTgAD mice through its capacity to
stabilize itself and accumulate in neurofibrillary tangles [26].
TPPP has recently been demonstrated (using electron microscopy)
Figure 7. Gene-ontology (GO) functional group analysis of up- or down-regulated protein sets from cortex and hippocampus from
3xTgAD animals. Panels A (cortex) and B (hippocampus) depict the significantly represented (p,0.05) functional GO groups and their relative
enrichment factor compared to background murine sets created by the up-regulated proteins (in 3xTgAD compared to control) identified in each
tissue. Panels C (cortex) and D (hippocampus) depict analogous data to Panels A and B but for input protein sets down-regulated in 3xTgAD
compared to control.
doi:10.1371/journal.pone.0002750.g007
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body-related disorders [27]. The scaffolding adapter 14-3-3
proteins may also be related to the structural subset of up-
regulated proteins in both the cortex and hippocampus. Indeed,
using immunohistochemistry it has been demonstrated that there
are significant correlations of 14-3-3 reactivity with elevated levels
of neurofibrillary tangles in AD [28]. Additionally, we identified
pigpen which is a nuclear protein with an RNA-binding motif and
a putative transcriptional activation domain [29] and is considered
to be a critical controller of transcriptional regulation in response
to trophic growth factors resulting in cell proliferation/differenti-
ation [30]. While evidence for a role of pigpen protein in the
pathology of AD is presently lacking, our demonstration of
increased pigpen levels in 3xTgAD brain tissue, suggests a role for
this protein in cellular responses to AD pathology.
With respect to the proteins involved in energy balance, there
seems to be a multi-faceted effect of the AD process in cortical and
hippocampal cells. Hence, some metabolism-related proteins were
co-upregulated (triosephosphate isomerase and vacuolar ATP
synthase subunit E), while others were co-downregulated (ATP
synthase beta chain and fructose-bisphosphate aldolase A) in the
cortex versus the hippocampus of the 3xTgAD mice. This
potential yin and yang of metabolic balance appears to flow through
many levels of the unbiased analysis of proteins whose expression
is significantly altered in AD pathology. The other primary co-
downregulated protein identified between the cortex and hippo-
campus was the diazepam binding inhibitor protein (DBI). DBI
was first isolated from rat and human brain, and is found almost
exclusively in GABAergic neurons where it is believed to inhibit
GABAergic neurotransmission [31]. DBI has been proposed to
block the binding of endogenous benzodiazepines (endozepines) to
the regulatory site present on the GABAA receptor, thus reducing
the regulation of the chloride channel current. Several reports
have also linked DBI to neurological disorders including AD,
Parkinson’s disease (PD) and schizophrenia [32]. Additionally, in
human hippocampal samples, an AD-related diminution (greater
than that observed in Parkinson’s disease) of the expression of DBI
has been demonstrated [33]. The functional correlates of this
reduction in DBI could be an adaptive response to the disruption
of synaptic strength which has been proposed to occur in AD, i.e.
inhibition of inhibitory signaling may serve to enhance an ailing
neurotransmitter system. Of course it is facile to also predict that
this effect could be a mediator of the neuropathologies of AD, i.e.a
decrease in inhibitory neurotransmission would also facilitate a
potential increase in excitotoxic neurotransmission events. This
potential duality of factors in a complex system such as the CNS
reinforces the need for a higher level of understanding of multiple
correlated factors (facilitated by quantitative proteomics) when
attempting to illuminate a complex disease process such as AD.
In contrast to the co-regulated proteins, fewer contra-regulated
proteins were observed between the cortex and hippocampus;
however, their identity suggests a differential activity status
between these two tissues in AD. Amongst proteins up-regulated
in the cortex, a structural bias is evident in that tubulins and heat
shock proteins were selectively up-regulated in the cortex while
they were down-regulated in the hippocampus; additionally,
energy-related proteins (enolase, pyruvate kinase and Na
+/K
+-
ATPase subunits) were a small sub-group of these proteins as well.
This suggests that either the hippocampus does not require an up-
regulation of metabolic proteins or that the cortex is undergoing a
Figure 8. Four-way Venn diagram analysis for significantly regulated GO functional groups in 3xTgAD compared to control from
cortex and hippocampus. A. Numbers of functional groups existing in the potential 15 loci in the Venn diagram between the four paradigms, i.e.
up- or down-regulation in cortex or hippocampus. B. Key for loci in the four-way Venn diagram in A. The functional groups represented in the
occupied loci are listed in Table 3.
doi:10.1371/journal.pone.0002750.g008
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more significant modification of its intermediary cell metabolism.
To further understand the molecular underpinning of AD, it is
useful to consider the contra-regulated proteins that were elevated
in the hippocampus but down-regulated in the cortex. One of
these contra-regulated proteins, parvalbumin, is a cytoplasmic
calcium binding protein that buffers intracellular Ca
2+, reducing
the activity of Ca
2+-dependent potassium channels, and thus
altering calcium-dependent neuronal firing patterns [34]. Parval-
bumin is primarily found in a subset of fast-spiking, inhibitory
GABAergic interneurons. Interestingly, parvalbumin-containing
neurons are very resistant to neurotoxic damage from ischemia
[35], epilepsy [36] and overt NMDA receptor stimulation [37].
Syntaxins are a group of synaptic plasma membrane proteins that
were first demonstrated to physically interact with PS-1 by Smith
et al. [38] and were subsequently shown, in vitro, to alter APP
processing via this interaction with PS-1, resulting in an
attenuation of secreted Ab [39]. It is also interesting to note that
in the hippocampus there is a specific up-regulation of ubiquitin,
perhaps in an attempt to attenuate the deleterious effects of Ab
and hyperphosphorylated tau upon the ubiquitin-proteasome
system (UPS: [40]). Taken together, these three proteins and their
relative regulation in the hippocampus, relative to the cortex,
suggests that perhaps the hippocampus is being preferentially
protected, potentially at the expense of cortical tissue. In this view,
the metabolic differences between the hippocampus and cortex
occur due to an excessive strain put on the cortex due to a
preferential rescue of hippocampal tissue.
When the proteins that were altered similarly in the cortex and
hippocampus of 3xTgAD mice compared to control mice were
analyzed according to functional groups (using Gene Ontology
terms), three significantly up-regulated protein sets were identified-
ATP-synthesis-coupled proton transport, neurotransmitter secre-
tion and synaptic transmission. From many lines of experimental
evidence it is clear that global energy management is crucial to
neuronal survival during times of stress and disease, and therefore
it is not surprising that proton transport links both tissues in our
study. Many anti-oxidant factors that play a neuroprotective role
in AD also aid in proton transport, including coenzyme Q-10
[41,42]. The functional groups of proteins that were present at
lower levels in the cortex and hippocampus of the 3xTgAD mice
consisted of proteins involved in glycolysis and a group of proteins
involved in neurite morphogenesis. The magnitude of the
functional group enrichment in the cortical samples is considerably
greater than that for the hippocampus (created by more proteins
being present in the cortical rather than the hippocampal sample
that cluster into this functional group), which again suggests that
the hippocampus is being preferentially protected during the
disease process. The general reduction in neurite morphogenesis is
presumably indicative of the considerable changes in the neural
networks, which may be related to impaired cognitive function in
the 3xTgAD mice [17].
Among the contra-regulated groups, two were present where
there was hippocampal up-regulation and cortical down-regula-
tion (cell-cell signaling, and regulation of neurotransmitter levels)
while only one functional group occurred with cortical up-
regulation and hippocampal down-regulation (K
+ transport). As
with the inferences from primary protein identification, the
classification into functional groups also hints at a hippocam-
pally-biased adaptive response, in that there is a more profound
control of neurotransmitter levels. Again whether this is indicative
of a heightened pathological load and thus a greater response to it
or a conserved protective mechanism to maintain short-term
memory remains to be conclusively determined.
Table 3. Four-way Venn diagram analysis of GO functional
group creation by up/down regulated protein sets from
cortex and hippocampus of 3xTgAD mice.
a b
Cell maturation Clathrin-coated endocytosis
Chromatin assembly Cu
2+ binding
Creatine kinase activity Calmodulin binding
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Specific loci are identified alphabetically according to Figure 8.
doi:10.1371/journal.pone.0002750.t003
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controlled by the multiple changes in protein expression that we
have described, it is reassuring to know that a coherent
demonstration of the accuracy of the protein identification was
achieved. Hence, we observed that the two co-upregulated KEGG
pathways in cortex and hippocampus were AD and neurodegen-
erative disorders. The significant presentation of these two KEGG
pathways reinforces the potential utility of this mass protein
identification and quantification technique coupled to an un-
biased functional annotation algorithm. In addition to the
expected alterations, novel signaling pathways also seemed to be
altered in the 3xTgAD mice, including insulin signaling which
suggests an alteration in trophic/metabolic regulation at the level
of the CNS. A substantial subset of contra-regulated KEGG
pathways were demonstrated that showed up-regulation in the
cortex and down-regulation in the hippocampus (gap junctions,
long-term depression [LTD], MAPK signaling, and regulation of
the actin cytoskeleton). The role of gap junction activity in the
pathophysiology of AD is presently unclear [43]; however,
increased expression of gap junction proteins such as connexin-
43 have been reported at the sites of amyloid plaques [44]. Also of
interest is the SNARE interaction pathway which was up-
regulated in the hippocampus, but not in the cortex, of the
3xTgAD mice. Due to the larger breadth of proteins included in
signaling pathways it is more likely that complex regulations of the
same pathway could occur in the same tissues. For example there
are several cases of signaling pathways that are both up- and
down-regulated in the same tissue, e.g. ATP synthesis is both up-
and down-regulated in the hippocampus, while the broad pathway
of proteins related to oxidative phosphorylation is up- and down-
regulated in both the cortex and hippocampus. These crossovers of
function may seem paradoxical, but could be indicative of a
Figure 9. Co- and contra-regulated GO functional groups created by up- and down- regulated protein sets from cortex and
hippocampus. Functional group enrichment factors for up-regulated functional groups (designated with UP arrow) from cortex and hippocampus
are shown alongside enrichment factors for down-regulated protein groups (designated with DOWN arrow).
doi:10.1371/journal.pone.0002750.g009
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ations (i.e., Ab and tau pathology) in the neurons of the 3xTgAD
mice.
From this study we have gained a greater appreciation of the
intricacies of the interaction between a multi-faceted disease
process and a complex neuronal system. In assessing the presence
of pathophysiology one must appreciate that the tissue or organ
that is diseased is not merely a passive entity and that its cells may
react in a specific manner to the imposed insult. Therefore
complicated signaling pathways and functional groups of proteins
may show both positive and negative regulation to create the
resultant phenotype. Because the 3xTgAD mice exhibit Ab
deposits, tau pathology, synaptic dysfunction, spatial learning
deficits and anxiety-like behaviors [17,45,46], the proteins and
pathways identified as being altered in the hippocampus and
cortex of the 3xTgAD mice may either contribute to the synaptic
dysfunction and behavioral abnormalities, or they could contribute
to neuroprotective responses of the neurons. By using proteomic
techniques, such as iTRAQ, to gain a deeper understanding of the
complex signaling pathways and functional groups of proteins that
are altered in AD, we could potentially open up novel therapeutic
avenues for the treatment of AD.
Materials and Methods
Tissue and protein extraction
The cortex and hippocampus were carefully dissected out from
8 male 16 month-old C57/BL6 control mice and 8 male 16
month-old 3xTgAD mice. All procedures were performed in
accordance with approved institutional protocols and were
approved by the Institutional Animal Care and Use Committee
of the National Institute on Aging. The tissues were homogenized
on ice with an NP-40-based cell lysis solution as described
previously [47], and subsequently the tissue was incubated at 4uC
for 1 hour with constant agitation. The lysate was then clarified by
centrifugation at 14,000 rpm for 15 minutes at 4uC. The total
protein concentration of the clarified lysate was measured and all
the samples were normalized to the same protein concentration
(1 mg/ml). A total of 50 mg of cortex or hippocampus protein
extract from each animal (control or 3xTgAD) was then pooled for
each isobaric iTRAQ (Applied Biosystems) mass tag label, i.e. 114,
115, 116 or 117. Thus, for the cortical 114 mass tag labeling
reaction, 50 mg of protein from control mouse 1 was added to
50 mg of protein from control mouse 2 (Figure S1). The same was
then performed for the hippocampal samples. Each mass tag
Figure 10. KEGG signaling pathway analysis of up- or down-regulated protein sets from cortex and hippocampus from 3xTgAD
animals. Panels A (cortex) and B (hippocampus) depict the significantly represented (p,0.05) KEGG signaling pathways and their relative
enrichment factor compared to background murine sets created by the up-regulated proteins (in 3xTgAD compared to control) identified in each
tissue. Panels C (cortex) and D (hippocampus) depict analogous data to Panels A and B but for input protein sets down-regulated in 3xTgAD
compared to control.
doi:10.1371/journal.pone.0002750.g010
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protein, obtained from two animals. Before labeling, and for the
preservation of the proteins, the total protein was precipitated into
a pellet using acidification with 30% tricholoroacetic acid.
iTRAQ
Protocol-iTRAQ chemistry labeling reagents were obtained from
Applied Biosystems. Control and 3xTgAD tissue samples were
treated in parallel throughout the labeling procedure. The generic
labeling protocol consisted of the following steps: protein reduction
and cysteine blocking, digestion of proteins with trypsin, labeling of
peptides with iTRAQ reagents, combining the samples that were to
be compared, strong cation exchange chromatography, desalting
with solid phase extraction, and LC/MS/MS analysis. Briefly,
protein sample pellets (generated by trichloroacetic acid precipita-
tion) were dissolved in dissolution buffer (0.5 M triethyammonium
bicarbonate, TEAB), to give a 5 mg/ml concentration. Subsequently,
20 ml( 1 0 0mg) of each mixture was aliquoted and 1 mld e n a t u r a n t
was added. Reducing reagent (2 ml) was added and the tubes were
incubated at 60uC for 1 hour. The proprietary (methyl methane-
thiosulphonate, Applied Biosystems) cysteine blocking reagent (1 ml)
was added and incubated for another 10 minutes at room
temperature. Trypsin (Promega) was reconstituted in water, 10 ml
of the solution containing 10 mgo ft r y p s i nw a sa d d e da n di n c u b a t e d
overnight at 37uC. Before labeling, the reagents were dissolved in
ethanol and the contents of one vial were transferred to a sample
tube. The labeling took place for 1 h at room temperature. The
following labels were used for cortical samples: 114-control (C1)-2
pooled C57/BL6 animals; 115-control (C2)-2 pooled C57/BL6
animals; 116-3xTgAD (C3)-2 pooled 3xTgAD animals; 117-
3xTgAD (C4)-2 pooled 3xTgAD animals. The following labels were
used for hippocampus samples: 114-control (H1)–2 pooled C57/
BL6 animals; 115-control (H2)-2 pooled C57/BL6 animals; 116-
3xTgAD (H3)–2 pooled 3xTgAD animals; 117-3xTgAD (H4)-2
pooled 3xTgAD animals. After labeling, the sample tubes, for
control and AD for separate tissues, were combined and dried down
to a volume of 50 ml to reduce the content of ethanol prior to strong
cation exchange (SCX) chromatography.
Western blot analysis
20 mg samples of the cortex or hippocampus were mixed with a
denaturing and reducing Laemmli buffer [47] and resolved by
SDS-PAGE. The proteins were then electrotransferred from the
gel onto a polyvinylenedifluoride (PVDF: NEN Life Sciences)
screen. The screen was treated with a Tris-buffered saline solution
supplemented with Tween-20, NP-40 and 4% bovine serum
albumin to block non-specific antibody interactions. Primary
antibodies (1:500–1000) were applied to the PVDF membrane for
1 hour at room temperature and proteins were identified by the
application of an alkaline-phosphatase-conjugated secondary
antibody (1:10000) that recognized the species type of the primary
antibody. The PVDF membrane was then exposed to an enzyme-
linked chemifluorescent developing substrate (Amersham Biosci-
ences) and was scanned using a GE Typhoon 9410 phosphor-
imager at a resolution of 100 mm. Western blot images were then
quantified using GE ImageQuant 5.1 software. The primary
antibodies were obtained from the following sources: ERK2,
tubulin, GaO, actin, 14-3-3-e, MAP-2, clathrin, parvalbumin-a,
HSP-90, syntaxin, GAPDH and protein kinase C were obtained
from Santa Cruz; ubiquitin, SOD, pyruvate kinase were obtained
Figure 11. Four-way Venn diagram analysis for significantly regulated KEGG signaling pathways in 3xTgAD compared to control
from cortex and hippocampus. A. Numbers of functional groups existing in the potential 15 loci in the Venn diagram between the four
paradigms, i.e. up- or down-regulation in cortex or hippocampus. B. Key for loci in the four-way Venn diagram in A. The functional groups
represented in the occupied loci are listed in Table 4.
doi:10.1371/journal.pone.0002750.g011
Proteomics in Alzheimer’s Mice
PLoS ONE | www.plosone.org 18 July 2008 | Volume 3 | Issue 7 | e2750from AbCam; cytochrome C was obtained from Cell Signaling
Technology; synaptophysin antibodies were obtained from Sigma.
Strong Cation Exchange Chromatography
SCX chromatography was employed to separate and resolve
labeled peptides as well as to remove excess reagents, MS
interfering compounds and undigested proteins. The SCX column
(75 mm610 cm: particles -C-18-AQ, 5 mm:120 A ˚: YMC) was
equilibrated with loading buffer (10 mM potassium phosphate in
25% acetonitrile, pH 3.0). The iTRAQ-labeled sample was
diluted 10x with loading buffer and then loaded on a PolyLC
PolySULFOETHYL A column. Subsequently, 200 mL, contain-
ing approximately 100 mg of peptides, was loaded onto the
column. Peptides were eluted at 50 ml/min in 40 min gradient,
using solvent A (10 mM potassium phosphate in 25% acetonitrile,
pH 3.0) and solvent B (350 mM KCl in 10 mM potassium
phosphate in 25% acetonitrile, pH 3.0). Absorbance at 280 nm
was monitored and ten 2 minute fractions were collected for
LCMS/MS analysis (Figures S2 and S3). The microflow HPLC
conditions employed for the cation exchange were applied using
an Agilent 1100 series capillary LC. Samples (3 ml) were passed
through a peptide trap into the LC column. A gradient was run
between 0.1% formic acid (A) and 90% acetonitrile: 0.1% formic
acid (B) as follows, 5% B to 40% B over 60 minutes. The flow rate
was 20 ml/min and was then split to 200 nl/min.
Mass Spectrometry analysis
An Applied Biosystems QStar mass spectrometer was used for
the isolation and collision-induced dissociation of input peptides.
The electrospray voltage typically maintained was 2.5kV. Mass
spectrometer calibration was performed with a mixture of CsI (MW
132.9049), synthetic peptide ALILTLVS (829.5393) and verapamil
(455.2904). The general conditions for mass ion identification and
isobaric mass tag resolution were: Scan Events: 1: Survey 400–1200
Da; 2–4: Data dependent MS/MS on 3 most intense ions from 1.
For collision energy: rolling collision energy (automatically set
according to the m/z of precursor), increased for 20% due to
iTRAQ tags. The exclusion time used for analysis was 60 seconds.
Mass tolerance was set to 0.15 atomic mass units for precursor and
0.1 atomic mass units for fragmented ions. Data analysis was
performed using the ProQuant program suit (Applied Biosystems).
Proteinidentificationwasperformedusingthemostrecentlyupdated
murine SwissProt database. Raw peptide identification results were
processed to generate a minimal set of proteins, as previously
described, using the Paragon Algorithm (Applied Biosystems)
[51,52]. Briefly, the raw peptide identification results from the
Paragon Algorithm searches were further processed by the
ProGroup Algorithm (Applied Biosystems) within the Protein Pilot
software before final display. The ProGroup Algorithm uses the
peptide identification results to determine the minimal set of proteins
that can be reported for a given protein confidence threshold. For
each protein ProGroup reports two score types for each protein:
unused ProtScore and total ProtScore. The total ProtScore is a
measurement of all the peptide evidence for a protein (analogous to
commonly reported protein scores). The unused ProtScore is a
measurement of all the peptide evidence for a protein that is not
betterexplainedbyahigherrankingprotein.HenceunusedProtScore
is calculated by using the unique peptides that are not linked to a
higher ranking protein. The protein confidence threshold cutoff for
this study was ProtScore 2.0 (unused) with at least two peptides with a
95% confidence. Proteins identified with mass tag changes (ratio
.1.2 or ,0.8) that were consistent between two independent
biological experiments were manually validated and quantified by
two independent analysts. These arbitrary cutoffs for expression
variation have been implemented by multiple researchers [51–55].
Peak areas for each of the signature ions (114, 115, 116, 117) were
obtained and corrected according to the manufacturers’ instructions
to account for isotopic overlap. Only those signature ions with
intensities less than 1500 counts were used for quantitation, greater
than 1500 counts results in detector saturation.
To calculate the relative protein levels, proteins with a statistically
significant label ratio of 116/117:114 greater or equal to 1.2 were
considered to be proteins elevated in 3xTgAD versus control
samples. Proteins with a significant label ratio of 116/117:114 less
than or equal to 0.8 were indicative of down-regulated proteins in
AD versus control. The relative expression level for ‘up-regulated’
proteins was calculated as follows: the mean 116/117:114 label ratio
was divided by the mean 115:114 label ratio. The eventual relative
expression level of ‘down-regulated proteins’ was calculated as
follows: the mean 115:114 label ratio was divided by the mean 116/
117:114 label ratio and then made negative to indicate the relative
direction of expression compared to control.
Supporting Information
Figure S1 Coomassie staining of protein extracts for iTRAQ
labeling. The extracted proteins (10 microgram samples per lane)
from control (C57/BL6: animals 1–4) or 3xTgAD mice (animals
5–8) are shown in a coomassie-stained SDS-PAGE gel. The
protein extracts from two pooled animal cortices or hippocampi
Table 4. Four-way Venn diagram analysis of significantly
regulated KEGG signaling pathway creation by up/down





Tight junction Glyoxylate metabolism
Urea cycle Long term potentiation (LTP)
Cell communication
c d
Amyotrophic lateral sclerosis Antigen processing/presentation
Parkinson’s disease Axon guidance
Phenylalanine metabolism Type II diabetes
Aspartate metabolism TCA cycle
Glutamate metabolism
f g
Alzheimer’s disease SNARE interactions
Neurodegenerative disorders
h i
Focal adhesions Insulin signaling
Gap junctions
Long term depression (LTD)
MAPK signaling




ATP synthesis Oxidative phosphorylation
Carbon fixation
Specific loci are identified alphabetically according to Figure 11.
doi:10.1371/journal.pone.0002750.t004
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bars underneath. The masses of the molecular mass markers on
the left of each gel represent, in descending order in kDa, 203,
119, 100, 51.9, 37.3, 29, 19.5 and 6.9.
Found at: doi:10.1371/journal.pone.0002750.s001 (0.39 MB TIF)
Figure S2 SCX UV trace and LC-MS/MS base peak
chromatograms for pooled samples of control or 3xTgAD cortex
samples. A. SCX UV Chromatogram (using 280nm wavelength
absorbance measurements of peptide bonds). Initial peak between
0–10 min contains SDS and other reagents from the iTRAQ
labeling reaction. B. LC-MS/MS base peak chromatogram of
fractions F1–F10 of the labeled and mixed cortex control/
3xTgAD samples from A.
Found at: doi:10.1371/journal.pone.0002750.s002 (0.08 MB TIF)
Figure S3 SCX UV trace and LC-MS/MS base peak
chromatograms for pooled samples of control or 3xTgAD
hippocampal samples. A. SCX UV Chromatogram (using
280nm wavelength absorbance measurements of peptide bonds).
Initial peak between 0–10 min contains SDS and other reagents
from the iTRAQ labeling reaction. B. LC-MS/MS base peak
chromatogram of fractions F1–F10 of the labeled and mixed
hippocampus control/3xTgAD samples from A.
Found at: doi:10.1371/journal.pone.0002750.s003 (0.08 MB TIF)
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